Tagomics

Tagomics is a UK precision medicine company developing a multiomic profiling technology that derives genomic, epigenomic and fragmentomic information from a single DNA sample through one streamlined workflow. Its platform combines detection of mutations (genomics), analysis of methylation and other chemical marks on the genome (epigenomics), and analysis of DNA fragmentation patterns in blood (fragmentomics), integrating the outputs with advanced data analysis and machine learning to identify new markers of disease.

The company applies this platform across two stated areas: oncology, focused on cancer detection, and organ health, focused on drug safety. Its Activace platform enables targeted, genome-wide profiling of unmethylated DNA regions for epigenomic biomarker discovery and liquid biopsy applications, work published in Cell Reports Methods. Tagomics has also introduced LiquiPath, described as a first-in-class cell-free DNA blood test for multi-organ drug safety monitoring across preclinical and clinical settings, accompanied by an early access programme for drug developers. Company-cited applications extend to age-related disease and biological age tracking, rare diseases and prenatal screening.

Founding story

Tagomics launched in July 2020 as a spinout from the University of Birmingham, built on research led by Dr Robert Neely of the University's School of Chemistry. That work, funded by an EPSRC Healthcare Technology Challenges award, sought to identify the earliest detectable changes to the genome during cancer through DNA methylation, and to develop technology capable of reading methylation where existing diagnostic tools struggle. The research produced three patents that were foundational to the company. Neely serves as Chief Scientific Officer and co-founder alongside CEO Dr Jack Kennefick, who is an inventor on three of the company's patents and a recipient of the Royal Society of Edinburgh Enterprise Fellowship.

Business model

Tagomics develops platform technology and diagnostic products, pursuing strategic partnerships to advance drug development and therapy selection, and has opened an early access programme for drug developers to shape future platform capabilities and applications.

Traction

Backing from Calculus Capital, Illumina Ventures, IQ Capital, Agilent Ventures, Mercia Ventures and others; three foundational patents; peer-reviewed publications in Cell Reports Methods and JCO Precision Oncology, the latter co-authored with AstraZeneca; and the launch of the LiquiPath product with an open early access programme.

Latest developments

Tagomics introduced LiquiPath, a cell-free DNA-based blood test for multi-organ drug safety monitoring across preclinical and clinical settings, opened an early access programme for drug developers, and launched a new brand identity and website marking expansion of its portfolio into organ health monitoring. Its Organ Health Programme Lead Dr John Gallon, Scientific Advisory Board member Professor Yuval Dor and partners at AstraZeneca co-authored a JCO Precision Oncology paper on using cell-free DNA to detect and monitor toxicity signals.